NantKwest to Host 4th Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
05 1월 2019 - 10:00PM
Business Wire
NantKwest (Nasdaq:NK), a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of the human immune system using natural killer (NK)
cells to treat cancer, infectious diseases and inflammatory
diseases today announced that the company will be hosting an
Investor/Analyst Day on Tuesday, January 8, 2019 in San Francisco,
California.
NantKwest will be sharing with analysts and investors a review
of the company’s activities in 2018 and provide an overview for
2019.
At this event, senior management of NantKwest will provide a
review of its ongoing R&D program, as well as provide a roadmap
for the company’s clinical programs for 2019.
The event will begin at 7:00 PM PT on Tuesday, January 8, 2019
and is expected to conclude at 9:00 PM PT. A replay of the
presentation will be posted on the NantKwest website and will be
available for 30 days following the event.
About NantKwest
NantKwest is an innovative clinical-stage immunotherapy company
focused on harnessing the power of the innate immune system by
using the natural killer cell to treat cancer, infectious diseases
and inflammatory diseases.
NantKwest is uniquely positioned to implement precision cancer
medicine, with the potential to change the current paradigm of
cancer care. Natural Killer cells are ancient cells in the human
body designed to recognize and detect cells under stress or
infected. The NantKwest “off-the-shelf” activated Natural Killer
(NK) platform is designed to destroy cancer and virally infected
cells from the body. The safety of our NK cells as well as their
activity against a broad range of cancers have been tested in
multiple phase 1 clinical trials in the United States, Canada and
Europe. In addition to our NK cells capability to be administered
in the outpatient setting as an “off-the-shelf” living drug, it
serves as a universal cell-based therapy without need for
individualized patient matching. Moreover, our NK cell based
platform has been bioengineered to incorporate chimeric antigen
receptors (CARs) and antibody receptors to potentially further
optimize targeting and potency in the therapeutic disease.
With the capacity to grow active killer cells as a biological
cancer therapy, NantKwest’s NK cells have been designed to induce
cell death against cancers and virally infected cells by multiple
modes of action that include: Direct killing via innate recognition
in which NK cells release toxic granules directly into the target
(diseased) cell through cell-to-cell contact; Antibody-mediated
killing using haNKs, which are NK cells engineered to incorporate a
high binding affinity receptor that binds to an administered
antibody, enhancing the cancer cell killing effect of that
antibody; Chimeric Antigen Receptor directed killing using the
taNK® platform, which includes NK cells engineered to incorporate
chimeric antigen receptors (CARs) to target tumor-specific antigens
found on the surface of cancer cells. All three modes of killing
(innate, antibody-mediated, and Chimeric Antigen Receptor directed
killing) using the t-haNK™ platform, which is an innovative
combination of our haNK® and taNK® platforms in a single cell.
Our haNK®, taNK®, and t-haNK™ platforms have been designed to
address certain limitations of T-cell therapies including the
reduction of risk of serious “cytokine storms.” As an
“off-the-shelf” therapy, NantKwest’s NK cells do not rely on a
patient’s own often compromised immune system. In Phase 1 clinical
trials in patients with late stage cancer, Nantkwest’s NK cells
have been administered as an investigational outpatient infusion
therapy without any reported severe side effects to date, even at
doses of 10 billion cells.
By leveraging an integrated and extensive genomics and
transcriptomics discovery and development engine, together with a
pipeline of multiple, clinical-stage, immuno-oncology programs, we
believe NantKwest is uniquely positioned to be the premier
immunotherapy company and transform medicine by delivering living
drugs in a bag and bringing novel NK cell-based therapies to
routine clinical care.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements concerning or
implying the Company will be successful in improving the treatment
of cancer. Risks and uncertainties related to this endeavor
include, but are not limited to, obtaining FDA approval of our NK
cells as well as other therapeutics as part of the NANT Cancer
Vaccine platform as a cancer treatment.
Forward-looking statements are based on management's current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements.
Accordingly, these forward-looking statements do not constitute
guarantees of future performance, and you are cautioned not to
place undue reliance on these forward-looking statements.
These and other risks regarding our business are described in
detail in our Securities and Exchange Commission filings, including
in our Quarterly Report on Form 10-Q for the quarter ended
September 30, 2018. These forward-looking statements speak only as
of the date hereof, and we disclaim any obligation to update these
statements except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190105005006/en/
For additional information please contact either of the
individuals below:
Media Contact:Jen Hodson562-397-3639Jen@nant.com
Investor Contact:David PyrceSVP, Innovation and Investor
RelationsCell 951-551-0949david.pyrce@nantkwest.com
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 7월(7) 2024 으로 8월(8) 2024
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 8월(8) 2023 으로 8월(8) 2024